A Phase II, Open Study to Assess Efficacy and Safety of Oral Rigosertib in Patients with Recessive Dystrophic Epidermolysis associated Locally Advanced/Metastatic Squamous Cell Carcinoma.
Phase of Trial: Phase II
Latest Information Update: 26 Dec 2017
At a glance
- Drugs Rigosertib (Primary)
- Indications Squamous cell cancer
- Focus Therapeutic Use
- 26 Dec 2017 New trial record